[ad_1]
January 06, 2026
2 min read
Key takeaways:
- Most patients used the iCare Home2 device multiple times per day.
- The device captures daily IOP fluctuations that occur outside the office.
IOP measurements taken at home with the iCare Home2 tonometer correlated closely with in-office measurements, according to a study published in Clinical Ophthalmology.
Most patients used the device multiple times per day, with significant swings in IOP occurring outside of clinic hours.
“In-office IOP monitoring provides only limited IOP surveillance, missing clinically relevant peaks and fluctuations that occur outside of office hours or from day to day,” Scott W. Perkins, a medical student at Cleveland Clinic Lerner College of Medicine, and colleagues wrote. “The iCare Home rebound tonometer was developed and FDA approved for patient home self-use, enabling over 75% of trained patients to take home IOP measurements that are accurate when compared to Goldmann applanation tonometry.”
Since then, a second-generation device, the iCare Home2 (iCare), has been released and shown reliability in studies, the researchers wrote. To take a closer look at patient adherence, daily IOP patterns and correlation with in-office measurements, they conducted a prospective cohort study of 75 patients with non-angle-closure glaucoma, suspected glaucoma or ocular hypertension. The patients were given an iCare Home2 device and instructed to use it six times per day for 10 ± 4 days.
According to the results, 65% of patients used the device six or more times per day, while a “notable minority” (19%) took fewer than two measurements per day. The researchers noted a bimodal distribution of measurements in which most patients took either between one and 25 measurements per day or between 75 and 125 measurements per day.
The six patients with fewer than two measurements per day reported their main barrier was “difficulty obtaining measurements,” while two reported having difficulties due to poor central vision, and two said they wanted more training on using the device.
The iCare Home2 measurements showed “good agreement” with in-office devices, the researchers wrote. They had significant positive correlations to measurements taken at the nearest point in time with Goldman applanation (P < .0001) or the iCare IC100 device (P < .0001).
On average, IOP peaked around 3 a.m. (22.2 ± 4.1 mm Hg) and decreased significantly during the day, reaching its lowest point at 10 p.m. (14.1 ± 4.2 mm Hg), the researchers wrote. More than one-third of eyes (36%) reached maximum IOP outside of clinic hours.
“Overall, this study demonstrates that home tonometry shows a more complete IOP profile of a patient compared to in-office tonometry, detecting risk factors that could inform management decisions,” Perkins and colleagues wrote. “These findings reinforce the utility of [iCare Home2] for comprehensive, reliable and practical IOP monitoring, with potential future applications for improved clinical risk stratification and management decision support.”
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
[ad_2]
Source link
